Indraprastha Medical Corporation Limited
Valuation (90/100) does the heavy lifting; momentum (9/100) is the drag.
Buy zoneIndraprastha Medical Corporation Limited earns a Buy from StocksWizard, with a blended score of 60/100. We put fair value near ₹674.01; at ₹366.35 that leaves roughly 84% upside, so the stock screens undervalued by 84%. On 18.3x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 41% below its 52-week high of ₹622.8 and 5% above the low of ₹349.5. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9. The average analyst target of ₹550 implies about 50% upside across 1 analysts. It clears 9 of 13 investability checks, with durability 74, valuation 79 and momentum 9 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹539.21.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-41.18% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy60Piotroski F-score 6/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 27.5%
- Pass: Low debt (D/E < 0.5): 0.05x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: 9%
- Pass: Earnings growing: 2%
- Pass: Net margin ≥ 10%: 12.4%
- Pass: Current ratio > 1.5: 2.46
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 10.16
- Fail: Piotroski ≥ 7: 6/9
Quarterly results
Annual financials
Shareholding
- Promoter55.3%
- Institutions0.6%
- Public & other44.0%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (27.5%).
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 10.16.
Opportunities
- Trading in our value buy zone versus sector peers.
- Well off its 52-week high — possible mean-reversion.
- Trades ~84% below our estimated fair value.
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
About Indraprastha Medical Corporation Limited
Indraprastha Medical Corporation Limited operates hospitals in India, providing specialized medical services including sugar management, genomic medicine, elder care, anesthesiology, bariatric and metabolic surgery, bone marrow transplant, dental and cosmetic services, dermatology, dietetics, vascular surgery, endocrinology, ENT, fetal medicine, general and laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, and IVF treatments.
Indraprastha Medical Corporation Limited — frequently asked questions
Is Indraprastha Medical Corporation Limited a buy, hold or sell?
StocksWizard currently rates Indraprastha Medical Corporation Limited (INDRAMEDCO) a Buy, based on a blended score of 60/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Indraprastha Medical Corporation Limited's fair value?
Our blended DCF and relative-valuation model estimates Indraprastha Medical Corporation Limited's fair value at about ₹674.01, versus a current price of ₹366.35 — roughly 84% upside. On that basis the stock looks undervalued by 84%.
Is Indraprastha Medical Corporation Limited financially healthy?
Indraprastha Medical Corporation Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9.
How has Indraprastha Medical Corporation Limited's share price performed?
Indraprastha Medical Corporation Limited is down 10% over three months, and last traded at ₹366.35. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.